Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21944766 | 0.88 | PRMT6 (0.33) | LTA4HDAO | |
| SCHEMBL26070335 | 0.84 | QPCT (0.32) | LTA4H | |
| SCHEMBL21945733 | 0.82 | CYP1A2 (0.38) | LTA4HDAO | |
| SCHEMBL26070494 | 0.80 | DAO (0.34) | DAO | |
| SCHEMBL21945716 | 0.77 | PGR (0.34) | RXRARXRBRXRG | |
| SCHEMBL21945193 | 0.76 | SLC6A2 (0.36) | RXRARXRBRXRG | |
| SCHEMBL26070403 | 0.76 | GPR84 (0.35) | — | |
| SCHEMBL18004264 | 0.76 | RXRA (0.36) | LTA4HHSP90AA1HSP90AB1RXRARXRB | |
| SCHEMBL21945136 | 0.76 | KDM4E (0.40) | HSP90AA1HSP90AB1 | |
| SCHEMBL26070407 | 0.76 | TOP2A (0.33) | DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | LTA4H 4154/4885HSP90AA1 3092/4885HSP90AB1 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.